SARS-CoV-2 -KIDS Study: Seroprevalence of SARS-CoV-2 (COVID-19) among children (<18y) in Germany: time series in sentinel children's hospitals

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 01KI20131A

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

  • Research Location

    Germany, Europe
  • Lead Research Institution

    Charité - Universitätsmedizin Berlin
  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease surveillance & mapping

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group

    Adolescent (13 years to 17 years)Children (1 year to 12 years)

  • Vulnerable Population


  • Occupations of Interest



SARS-CoV-2 is spreading rapidly and globally, but little is known about the distribution and mode of spreading in Germany. Since it is expected that COVID-19 will be comparatively harmless or even asymptomatic in children, it can be assumed that a high number of infections in this group will be not detected, causing children to act as spreaders of the infection. The aim of this study is to obtain a prospective monthly estimate of the seroprevalence of an infection with the SARS-CoV-2 in children and adolescents in Germany in the period from 01.05.2020 to 30.04.2021 in 12 sentinel children's hospitals and thereby describe the yearly course of the epidemic in children and adolescents: • What is the maximum prevalence reached at the peak of the epidemic? • When does the monthly increment flatten? • Are there differences with the temporal course by age, sex, and region? • What is the estimated burden of suffering related to the SARS-Cov-2 in children? • Does the burden of suffering vary by age, sex, ethnicity or underlying disease? • Which proportion of confirmed positive cases has been previously diagnosed by a physician or other medical experts? Data on the seroprevalence of SARS-CoV-2 in children are mandatory for understanding the previous epidemiology and for guidance of the management of the epidemic in the future.